BACKGROUND: Group differences in brain structure between methamphetamine-dependent and healthy research participants have been reported, but findings in the literature present discrepancies. Although most methamphetamine-abusing individuals also smoke cigarettes, the effects of smoking on brain structure have not been distinguished from those of methamphetamine. Changes with abstinence from methamphetamine have also been relatively unexplored. This study, therefore, attempted to account for effects of smoking and brief abstinence from methamphetamine on gray-matter measures in methamphetamine-dependent research participants. METHODS: Gray matter was measured using voxel-based morphometry in three groups: 18 control nonsmokers, 25 control smokers, and 39 methamphetamine-dependent smokers (methamphetamine-abstinent 4-7 days). Subgroups of methamphetamine-dependent and control participants (n=12/group) were scanned twice to determine change in gray matter over the first month of methamphetamine abstinence. RESULTS: Compared with Control Nonsmokers, Control Smokers and Methamphetamine-dependent Smokers had smaller gray-matter volume in the orbitofrontal cortex and caudate nucleus. Methamphetamine-dependent Smokers also had smaller gray-matter volumes in frontal, parietal and temporal cortices than Control Nonsmokers or Smokers, and smaller gray-matter volume in insula than control nonsmokers. Longitudinal assessment revealed gray matter increases in cortical regions (inferior frontal, angular, and superior temporal gyri, precuneus, insula, occipital pole) in methamphetamine-dependent but not control participants; the cerebellum showed a decrease. CONCLUSIONS: Gray-matter volume deficits in the orbitofrontal cortex and caudate of methamphetamine-dependent individuals may be in part attributable to cigarette smoking or pre-morbid conditions. Increase in gray matter with methamphetamine abstinence suggests that some gray-matter deficits are partially attributable to methamphetamine abuse.
BACKGROUND: Group differences in brain structure between methamphetamine-dependent and healthy research participants have been reported, but findings in the literature present discrepancies. Although most methamphetamine-abusing individuals also smoke cigarettes, the effects of smoking on brain structure have not been distinguished from those of methamphetamine. Changes with abstinence from methamphetamine have also been relatively unexplored. This study, therefore, attempted to account for effects of smoking and brief abstinence from methamphetamine on gray-matter measures in methamphetamine-dependent research participants. METHODS: Gray matter was measured using voxel-based morphometry in three groups: 18 control nonsmokers, 25 control smokers, and 39 methamphetamine-dependent smokers (methamphetamine-abstinent 4-7 days). Subgroups of methamphetamine-dependent and control participants (n=12/group) were scanned twice to determine change in gray matter over the first month of methamphetamine abstinence. RESULTS: Compared with Control Nonsmokers, Control Smokers and Methamphetamine-dependent Smokers had smaller gray-matter volume in the orbitofrontal cortex and caudate nucleus. Methamphetamine-dependent Smokers also had smaller gray-matter volumes in frontal, parietal and temporal cortices than Control Nonsmokers or Smokers, and smaller gray-matter volume in insula than control nonsmokers. Longitudinal assessment revealed gray matter increases in cortical regions (inferior frontal, angular, and superior temporal gyri, precuneus, insula, occipital pole) in methamphetamine-dependent but not control participants; the cerebellum showed a decrease. CONCLUSIONS: Gray-matter volume deficits in the orbitofrontal cortex and caudate of methamphetamine-dependent individuals may be in part attributable to cigarette smoking or pre-morbid conditions. Increase in gray matter with methamphetamine abstinence suggests that some gray-matter deficits are partially attributable to methamphetamine abuse.
Authors: Timothy C Durazzo; Valerie A Cardenas; Colin Studholme; Michael W Weiner; Dieter J Meyerhoff Journal: Drug Alcohol Depend Date: 2006-09-06 Impact factor: 4.492
Authors: José V Manjón; Jussi Tohka; Gracian García-Martí; José Carbonell-Caballero; Juan J Lull; Luís Martí-Bonmatí; Montserrat Robles Journal: Magn Reson Med Date: 2008-04 Impact factor: 4.668
Authors: Osvaldo P Almeida; Griselda J Garrido; Nicola T Lautenschlager; Gary K Hulse; Konrad Jamrozik; Leon Flicker Journal: Am J Geriatr Psychiatry Date: 2008-01 Impact factor: 4.105
Authors: S M Berman; B Voytek; M A Mandelkern; B D Hassid; A Isaacson; J Monterosso; K Miotto; W Ling; E D London Journal: Mol Psychiatry Date: 2007-10-16 Impact factor: 15.992
Authors: Gerard R Ridgway; Rohani Omar; Sébastien Ourselin; Derek L G Hill; Jason D Warren; Nick C Fox Journal: Neuroimage Date: 2008-09-20 Impact factor: 6.556
Authors: I K Lyoo; S Yoon; T S Kim; S M Lim; Y Choi; J E Kim; J Hwang; H S Jeong; H B Cho; Y A Chung; P F Renshaw Journal: Mol Psychiatry Date: 2015-02-10 Impact factor: 15.992
Authors: Andy C Dean; Milky Kohno; Angelica M Morales; Dara G Ghahremani; Edythe D London Journal: Drug Alcohol Depend Date: 2015-03-18 Impact factor: 4.492
Authors: Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis Journal: Pharmacol Biochem Behav Date: 2019-01-26 Impact factor: 3.533
Authors: Samantha J Fede; Carla L Harenski; Jana Schaich Borg; Walter Sinnott-Armstrong; Vikram Rao; Brendan M Caldwell; Prashanth K Nyalakanti; Michael R Koenigs; Jean Decety; Vince D Calhoun; Kent A Kiehl Journal: Psychopharmacology (Berl) Date: 2016-07-12 Impact factor: 4.530
Authors: Angelica M Morales; Dara Ghahremani; Milky Kohno; Gerhard S Hellemann; Edythe D London Journal: Neuropsychopharmacology Date: 2014-03-03 Impact factor: 7.853